Why anti-cancer drugs do not always live up to expectations

For more than a decade, researchers have watched a promising class of cancer drugs repeatedly fail in human trials. Now, scientists at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg, Germany, may finally understand why—and what to do about it.

The drugs in question are called BET inhibitors. The theory behind them was straightforward: many cancers depend on oncogenes that BET proteins help activate, so blocking those proteins should slow tumor growth. In laboratory experiments, it worked beautifully. In patients, the results were mostly disappointing—limited responses, significant side effects, and no reliable way to predict which tumors would respond at all.

Writing in Nature Genetics, the team led by Asifa Akhtar reveals that the problem lies in how we understood the target to begin with. BET inhibitors were designed to block a shared feature across the entire BET protein family, assuming they all performed roughly the same function. The Freiburg researchers found the opposite is true.

Using super-resolution microscopy, they discovered that two key BET proteins—BRD2 and BRD4—operate at completely different stages of gene activation. BRD4 drives what most current therapies target: releasing RNA Polymerase II, the enzyme that pushes genes into active transcription. But BRD2 acts far earlier, recruiting and organizing the molecular machinery that gets transcription started in the first place.

"Think of gene activation like stage production," says Akhtar. "BRD2 sets up the stage: assembling the props, costumes and actors to ensure preparations run smoothly. BRD2 then gives BRD4, the actor, the 'start' signal to begin with the performance." She notes that previous research had focused almost entirely on the performance itself, overlooking the critical setup work preceding it.

The implication is significant: current inhibitors that block both proteins simultaneously are disrupting two different steps of the same process at once, producing effects that are unpredictable and highly dependent on context—exactly the pattern seen in those disappointing clinical trials.

The study goes deeper still. BRD2's unique role depends on its sensitivity to chemical "bookmarks" placed on chromatin by an enzyme called MOF. These histone acetylations tell BRD2 where to begin its organizing work. Remove MOF, and BRD2 loses its grip on chromatin while other BET proteins remain largely unaffected. Beyond this specificity, BRD2 actively organizes the transcription machinery spatially, forming dynamic clusters at gene binding sites that concentrate the necessary molecular components precisely where they are needed.

First author Umut Erdogdu from the Akhtar lab explains that when his team removed only the specific part of BRD2 responsible for forming these clusters—leaving the rest of the protein intact—the results were striking. The discovery suggests future therapies might achieve better results by targeting BRD2's distinct functions rather than broadly inhibiting the entire BET family.

The findings point toward a more precise mode of cancer therapy: one that understands the difference between the stage manager and the actor, rather than silencing both at once.